Post-marketing safety assessment of mirvetuximab soravtansine: a disproportionality analysis based on the FDA Adverse Event Reporting System.
OBJECTIVE Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate that targets the folate receptor-alpha and is used for the treatment of platinum-resistant ovarian cancer, though post-marketing safety data remain limited. This study aimed to perform a post-marketing safety assessment of MIRV based on the Food a...